NewsSOS
Early human trials of the experimental injection CBL-514 demonstrated a 12.01% reduction in visceral fat volume among participants, according to data reported by SciTechDaily.
Visceral fat accumulates deep within the abdomen around internal organs and is linked to metabolic dysfunction, insulin resistance, and type 2 diabetes.
The American Heart Association published research in March stating that visceral fat has a stronger association with heart failure risk than body mass index (BMI).
Garvey, affiliated with the University of Alabama at Birmingham, and Yu-Fang Ling of Caliway Biopharmaceuticals in New Taipei City, Taiwan, led the investigation.
Keep reading